Annual short term debt:
$22.22M+$16.06M(+260.89%)Summary
- As of today (September 18, 2025), RXRX annual short term debt is $22.22 million, with the most recent change of +$16.06 million (+260.89%) on December 31, 2024.
- During the last 3 years, RXRX annual short term debt has risen by +$20.71 million (+1375.43%).
- RXRX annual short term debt is now at all-time high.
Performance
RXRX Short term debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly short term debt:
$20.48M+$44.00K(+0.22%)Summary
- As of today (September 18, 2025), RXRX quarterly short term debt is $20.48 million, with the most recent change of +$44.00 thousand (+0.22%) on June 30, 2025.
- Over the past year, RXRX quarterly short term debt has increased by +$3.77 million (+22.54%).
- RXRX quarterly short term debt is now -7.81% below its all-time high of $22.22 million, reached on December 31, 2024.
Performance
RXRX quarterly short term debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Short term debt Formula
Short-Term Debt = Current Portion of Long-Term Debt + Short-Term Loans + Commercial Paper + Other Short-Term Borrowings
RXRX Short term debt Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +260.9% | +22.5% |
| 3 y3 years | +1375.4% | +284.0% |
| 5 y5 years | +3984.6% | - |
RXRX Short term debt Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +1375.4% | -7.8% | +301.6% |
| 5 y | 5-year | at high | +3984.6% | -7.8% | +1262.0% |
| alltime | all time | at high | +3984.6% | -7.8% | +1262.0% |
RXRX Short term debt History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $20.48M(+0.2%) |
| Mar 2025 | - | $20.44M(-8.0%) |
| Dec 2024 | $22.22M(+260.9%) | $22.22M(+35.1%) |
| Sep 2024 | - | $16.45M(-1.6%) |
| Jun 2024 | - | $16.72M(+173.3%) |
| Mar 2024 | - | $6.12M(-0.6%) |
| Dec 2023 | $6.16M(+1.8%) | $6.16M(+1.8%) |
| Sep 2023 | - | $6.05M(+2.6%) |
| Jun 2023 | - | $5.89M(+15.6%) |
| Mar 2023 | - | $5.10M(-15.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2022 | $6.05M(+301.7%) | $6.05M(+7.3%) |
| Sep 2022 | - | $5.64M(+5.6%) |
| Jun 2022 | - | $5.33M(+27.7%) |
| Mar 2022 | - | $4.18M(+177.4%) |
| Dec 2021 | $1.51M(-2.2%) | $1.51M(+0.1%) |
| Sep 2021 | - | $1.50M(-58.6%) |
| Jun 2021 | - | $3.63M(+37.4%) |
| Mar 2021 | - | $2.64M(+71.7%) |
| Dec 2020 | $1.54M(+183.1%) | - |
| Dec 2020 | - | $1.54M |
| Dec 2019 | $544.00K | - |
FAQ
- What is Recursion Pharmaceuticals, Inc. annual short term debt?
- What is the all time high annual short term debt for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. annual short term debt year-on-year change?
- What is Recursion Pharmaceuticals, Inc. quarterly short term debt?
- What is the all time high quarterly short term debt for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. quarterly short term debt year-on-year change?
What is Recursion Pharmaceuticals, Inc. annual short term debt?
The current annual short term debt of RXRX is $22.22M
What is the all time high annual short term debt for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high annual short term debt is $22.22M
What is Recursion Pharmaceuticals, Inc. annual short term debt year-on-year change?
Over the past year, RXRX annual short term debt has changed by +$16.06M (+260.89%)
What is Recursion Pharmaceuticals, Inc. quarterly short term debt?
The current quarterly short term debt of RXRX is $20.48M
What is the all time high quarterly short term debt for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high quarterly short term debt is $22.22M
What is Recursion Pharmaceuticals, Inc. quarterly short term debt year-on-year change?
Over the past year, RXRX quarterly short term debt has changed by +$3.77M (+22.54%)